Ongoing treatment(s)-Biological therapy-Targeted Therapy Page 2 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy-Targeted Therapy Posts on Medivizor

Drug interactions with tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Jul 17, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the interactions between tyrosine kinase inhibitors and other drugs taken at the same time in patients with chronic myeloid leukemia. This study concluded that drug interactions were found in a significant number of patients, with mild side effects. Some background Imatinib (Gleevec) and similar drugs are the...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More

A new treatment combination for patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients.     Some background Chronic lymphocytic leukemia...

Read More

Treatment options for chronic myeloid leukemia patients with failed imatinib treatment

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna) in chronic phase chronic myeloid leukemia patients with failed imatinib (Gleevec) treatment. This study concluded that dasatinib and nilotinib were safe and effective in this group of patients. Some background Chronic...

Read More

A new option for chronic myeloid leukemia patients who have an intolerance to TKIs

Posted by on Mar 27, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...

Read More

Are different types of BCR-ABL1 transcripts associated with different outcomes?

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study examined outcomes in chronic myeloid leukemia (CML) patients with different types of a genetic abnormality known as BCR-ABL1. While patients with the BCR-ABL transcript e14a2 showed better response to treatment, long-term outcomes were similar between groups. Some background Certain genetic changes in CML can make it more...

Read More

An overview of the dose management of dasatinib

Posted by on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...

Read More

Promising early results with venetoclax in patients previously treated with idelalisib

Posted by on Jan 18, 2018 in Leukemia | 0 comments

In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...

Read More

Remission rates after discontinuation of imatinib

Posted by on Nov 7, 2017 in Leukemia | 0 comments

In a nutshell This study examined outcomes after discontinuation of imatinib (Gleevac) in patients with chronic myeloid leukemia (CML). Researchers reported that some CML patients can safely discontinue imatinib after achieving a deep treatment response. Factors such as detectable residual leukemia cells after treatment affect the risk of losing...

Read More